Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954859 | 0.82 | TAAR1 (0.43) | IDO1ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL7521671 | 0.78 | MAOB (0.43) | MAOBIDO1ALDH1A1POLBTDP1 | |
| SCHEMBL1372734 | 0.77 | TAAR1 (0.38) | IDO1ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL30313045 | 0.77 | MAOB (0.45) | MAOBIDO1ALDH1A1POLBTDP1 | |
| SCHEMBL41933 | 0.76 | MAOB (0.47) | MAOBIDO1ALDH1A1POLBTDP1 | |
| SCHEMBL28116266 | 0.76 | PNMT (0.43) | PNMTDPP4 | |
| SCHEMBL43013 | 0.76 | IDO1 (0.61) | MAOBIDO1ALDH1A1POLBTDP1 | |
| Hydrochloric Acid SCHEMBL18344819 | 0.76 | MAOB (0.46) | MAOBIDO1ALDH1A1POLBTDP1 | |
| SCHEMBL15550999 | 0.75 | TAAR1 (0.39) | IDO1ALDH1A1TDP1L3MBTL1TAAR1 | |
| SCHEMBL2776951 | 0.75 | STIM1 (0.42) | TAAR1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118679-A1 | N-Methyl Pyrazoles | Prosetta Antiviral ,Inc. | 2018-05-03 | — | — | US | disclosed |
| US-20180118679-A1 | N-Methyl Pyrazoles | Prosetta Antiviral ,Inc. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118679-A1 | N-Methyl Pyrazoles | ZC3HAV1, MAVS, NNMT | MAOB 3088/4885IDO1 973/4885ALDH1A1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.